NEW YORK (GenomeWeb News) – Laboratory Corporation of America today reported revenue growth of 1 percent for the second quarter of 2012, missing analysts' consensus estimate on the top line.

The Burlington, NC-based clinical lab firm reported total revenues of $1.42 billion for the three-month period ended June 30, compared to $1.40 billion for the second quarter of 2011. It fell short of Wall Street's consensus revenues estimate of $1.44 billion.

LabCorp said that testing volume in the quarter was essentially flat, while revenue-per-requisition increased 1.5 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.